Key Points
Question
Is the risk of stroke increased in patients experiencing nonarteritic anterior ischemic optic neuropathy (NAION) compared with a matched control population?
Findings
This multinational cohort study of 89 811 patients with NAION found a significantly elevated risk of stroke following NAION compared with 89 811 propensity score–matched patients without NAION, over both short-term and long-term periods, irrespective of comorbidities.
Meaning
These findings suggest the possible necessity for regular stroke workup following the onset of NAION.
This multinational cohort study examines short-term and long-term stroke risk among patients with nonarteritic anterior ischemic optic neuropathy compared with a matched control group.
Abstract
Importance
The association between nonarteritic anterior ischemic optic neuropathy (NAION) and an increased risk of stroke has been a subject of debate. However, multinational studies on this topic are scarce.
Objective
To evaluate the short-term and long-term stroke risk after NAION compared with a matched control group.
Design, Setting, and Participants
This global, retrospective, population-based cohort study used aggregated electronic health records from January 1, 2004, through March 19, 2024, sourced from the Global Collaborative Network of TriNetX, which includes data from over 152 million patients across 17 countries. Patients in the study were followed up for a maximum duration of 10 years. Patients with NAION and age-related cataract were included in the analysis. Those with stroke before the diagnosis of NAION and age-related cataract were excluded. Propensity score matching was applied to balance age, sex, race, ethnicity, comorbidities, and medication use.
Exposure
International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10) diagnosis code for NAION or age-related cataract.
Main Outcomes and Measures
The primary outcome was the relative risk (RR) of stroke (ICD-10 code I60-63) in the NAION cohort vs the matched controls. Multivariable logistic regression analyses were applied to identify potential clinical factors associated with stroke within the NAION cohort.
Results
A total of 89 811 patients were identified in both the NAION (mean [SD] age, 57.2 [18.5] years; 38 678 men [43.1%]) and control (mean [SD] age, 57.0 [17.9] years; 40 014 men [44.6%]) cohorts after matching. The NAION cohort demonstrated a significantly higher all-stroke risk at all time points: 1 month (RR, 5.04; 95% CI, 4.41-5.78), 3 months (RR, 3.79; 95% CI, 3.40-4.21), 1 year (RR, 2.50; 95% CI, 2.32-2.70), 5 years (RR, 1.54; 95% CI, 1.45-1.63), and 10 years (RR, 1.33; 95% CI, 1.23-1.43). Sensitivity analysis in patients without comorbidities similarly revealed a significantly increased all-stroke risk across all intervals: 1 month (RR, 7.55; 95% CI, 4.74-12.03), 3 months (RR, 6.70; 95% CI, 4.48-10.04), 1 year (RR, 3.96; 95% CI, 2.94-5.34), 5 years (RR, 2.85; 95% CI, 2.18-3.72), and 10 years (RR, 1.68; 95% CI, 1.25-2.26). Among all the clinical factors of interest, only hypertension was consistently associated with all subtypes of stroke following NAION.
Conclusions and Relevance
This cohort study of patients with NAION found a significantly elevated risk of stroke compared with matched controls, independently of comorbidities. These findings underscore the importance of regular stroke workups following the onset of NAION.
Introduction
Nonarteritic anterior ischemic optic neuropathy (NAION) is characterized by abrupt, painless vision loss and is one of the leading causes of blindness in adults.1 It is the most frequently occurring acute optic neuritis in those older than 50 years and is second only to glaucoma in overall optic neuropathy prevalence.2 The multifaceted pathophysiology of NAION is not entirely elucidated, but the hypoperfusion of the small arteries and arterioles supplying the optic nerve head is believed to be a primary factor.1 Incidence rates of NAION are reported to range from 2.3 to 82 cases per 100 000 person-years,1,2,3,4 predominantly affecting older adults with a spectrum of systemic risk factors.1,5 Interestingly, a number of risk factors are shared between NAION and stroke, with notable ones being diabetes, obstructive sleep apnea, smoking, dyslipidemia, hypertension, and cardiovascular diseases.5,6,7,8 This association has prompted investigations into the potential elevation of stroke risk in patients with NAION. The inquiry into the association between NAION and stroke risk, however, has yielded inconclusive and varied findings.3,9,10,11,12,13,14 Some studies3,9,10 indicate a considerably higher risk of stroke in patients with NAION with comorbid conditions, yet the extent of risk across the whole NAION population is still a matter of debate.
Notwithstanding the volume of research conducted on the subject, the lack of multinational studies represents a noteworthy limitation. Predominantly, the extant literature is limited to single-center9,10,12,14 or single-country3,11,13 investigations, often with racially homogeneous participant cohorts.3,11,13,14 To bridge the extant research gap, our study seeks to use TriNetX, an international, aggregated electronic medical record database, to evaluate the stroke risk after NAION in comparison with a matched control population.
Methods
Study Population
This study used data from the TriNetX Research Network, which contains real-time information on more than 250 million patients from 127 health care organizations. The data used in this study were collected on July 30, 2024. We focused on the Global Collaborative Network, comprising 127 health care organizations across 17 countries with 152 387 781 patients. This study was approved by the institutional review board of the Chi Mei Medical Center and conducted under the principles of the Declaration of Helsinki.15 The necessity for obtaining informed consent was exempted given that the study was based exclusively on aggregated data and statistical summaries derived from deidentified information, in accordance with 45 CFR §46. No protected health information was accessed, and no study-specific interventions were conducted in this retrospective analysis. This research adhered to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guidelines, ensuring compliance with reporting standards.16
Study Design
This retrospective cohort study was conducted over a 20-year interval, commencing on January 1, 2004, and concluding on March 19, 2024. Inclusion criteria encompassed all incident cases of NAION identified within the time frame of January 1, 2004, to March 19, 2023, thereby ensuring a minimum of 1-year follow-up after diagnosis for each patient. Mortality within the first year after diagnosis did not preclude data inclusion in the study’s analysis.
For the identification of incident NAION cases, we used the H47.0 diagnostic code in accordance with the International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10), which was also used in other studies.11,17 The index date was determined as the date of the earliest claim using the NAION diagnostic code.
Exclusion criteria were defined to omit patients with conditions that could potentially be confounded with NAION throughout the study period. This included patients with diagnoses of giant cell arteritis (ICD-10 codes M31.5 and 31.6), polymyalgia rheumatica (ICD-10 code M35.5), multiple sclerosis (ICD-10 code G35), optic neuritis (ICD-10 code H46), and other demyelinating diseases of the central nervous system (ICD-10 code G36) including neuromyelitis optica. Patients with a stroke (ICD-10 codes I60-63) before the index date were likewise excluded. Subsequent to applying these criteria, a cohort of 104 996 patients with NAION diagnosed between 2004 and 2023 was established for analysis.
Baseline characteristics such as age at event, race, ethnicity, and sex were documented. Race and ethnicity data were included in our study as potential covariates and were reported by the health care institutions collaborating with the TriNetX platform. Furthermore, an assessment of comorbidities and comedication usage was conducted to identify potential confounders in the association between NAION and subsequent stroke risk. The presence of comorbidities and the usage of comedications were determined on the basis of historical diagnoses and prescription records up to 2 years before the index date. Comorbidities of interest included diabetes, obstructive sleep apnea, dyslipidemia, hypertension, heart failure, atrial fibrillation and/or flutter, ischemic heart diseases, chronic kidney disease, morbid obesity, tobacco use, and alcohol-related disorder. In addition, specific cerebrovascular diseases, such as cerebral aneurysm, vascular malformations (including arteriovenous malformation, dural arteriovenous fistula, and others), and steno-occlusive vasculopathy, were also included. Furthermore, conditions associated with elevated homocysteine levels, including vitamin B12 deficiency and disorders of sulfur-bearing amino acid metabolism, were identified (see eTable 1 in Supplement 1 for relevant ICD-10 codes). Information on comedication encompassed the use of antiplatelet agents, anticoagulant agents, antilipemic agents, oral hypoglycemic agents, insulin, α-blockers, β-blockers, calcium channel blockers, diuretics, angiotensin-converting enzyme inhibitors, and angiotensin II receptor blockers (see eTable 1 in Supplement 1 for detailed drug codes).
A control group was subsequently established, consisting of patients with initial diagnoses of age-related cataracts between January 1, 2004, and March 19, 2023. This ensured that the control cases also had at least 1 year of follow-up. If patients died within 1 year, they were still included in the analysis. To identify the controls with age-related cataracts, we used the ICD-10 code H25. Patients who had experienced a stroke before the diagnosis of age-related cataracts were excluded. Furthermore, any patient in the cataract control group was excluded if they experienced an NAION event during the study period. On the basis of these criteria, 2 001 698 patients with age-related cataract diagnosed between 2004 and 2023 were included.
Main Outcomes
The primary outcome of this study was to assess the rate of all stroke (ICD-10 codes I60-63) at various time intervals: 1 month, 3 months, 1 year, 5 years, and 10 years. Furthermore, the rates of ischemic stroke (ICD-10 code I63) and hemorrhagic stroke (ICD-10 codes I60-62) were separately quantified at these identical time points. Analyses at the 5-year and 10-year marks were restricted to patients with a minimum corresponding follow-up period. Cases of mortality within these intervals were not excluded from the analysis. The relative risk (RR) and risk difference (RD) were calculated to compare the risk of outcomes between the NAION cohort and the cataract control group.
Statistical Analysis
Statistical analyses were performed using SPSS statistical software version 19 (IBM) and the built-in statistical function of the TriNetX network. Propensity score matching (PSM) was used to equilibrate baseline characteristics such as age, sex, race, ethnicity, the aforementioned comorbidities, and comedications between the NAION and cataract control cohorts. We used a logistic regression model to optimize the variates of the 2 cohorts, and the closest propensity scores were estimated. Matching (1:1) by nearest-neighbor greedy matching algorithm with a caliper of 0.1 SD was used to derive matched pairs. The propensity score, denoting the likelihood of exposure to either NAION or cataract control patients, was determined using the baseline characteristics of age, sex, race, ethnicity, the aforementioned comorbidities, and comedications adjusted into the regression model.18 The use of nearest-neighbor greedy matching with a caliper width of 0.1 pooled SD algorithm imposes a maximum difference in propensity scores between NAION and cataract control patients within a matched pair, leading to less-biased estimates than other matching algorithms.19 Standardized mean difference (SMD) was performed to analyze the homogeneity of category variables, including age, sex, race, ethnicity, comorbidities, and comedications between the NAION and cataract control cohorts. SMD greater than 0.1 indicates a significant difference between the 2 groups.20 Considering the presence of 2 types of stroke, the Bonferroni correction was used to adjust for multiple comparisons. P < .025 was considered statistically significant.
Risk Factor Analysis
Risk factor analysis was conducted to evaluate the association between clinical factors of interest and stroke within the NAION cohort. These clinical factors included age, sex, and comorbidities. Logistic regressions using multivariable analyses were applied.
Sensitivity Analysis
To discern the isolated association of NAION with stroke risk, a sensitivity analysis was performed of patients without comorbidities. This involved excluding those with any diagnostic claim for the aforementioned comorbidities during the study period from both cohorts. Following this refinement, PSM with 1:1 matching by age, sex, race, ethnicity, and the aforementioned comedications was conducted for the remaining patients within both cohorts. Rates of all stroke, ischemic stroke, and hemorrhagic stroke were then evaluated at the same time intervals specified in the primary analysis. Consistent with the primary analysis, only patients with at least 5 or 10 years of follow-up were included in the analyses performed at the corresponding intervals, whereas cases of mortality within these periods were retained in the analysis. RR and RD were also calculated for each interval.
Results
Baseline Demographic and Clinical Characteristics
A total of 89 811 patients were included in both the NAION (mean [SD] age, 57.2 [18.5] years; 49 700 women [55.3%]; 38 678 men [43.1%], 1433 unknown [1.6%]) and cataract control (mean [SD] age, 57.0 [17.9] years; 47 954 women [55.4%]; 40 014 men [44.6%], 1843 unknown [2.1%]) cohorts after PSM. Race distribution in the NAION cohort was 0.3% American Indian or Alaska Native (268 individuals), 4.4% Asian (3965 individuals), 11.5% Black or African American (10 326 individuals), 0.6% Native Hawaiian or Other Pacific Islander (571 individuals), 55.4% White (49 739 individuals), 3.3% other race (which includes multiracial and any other race not specified; 2937 individuals), and 24.5% unknown (22 005 individuals). In the cataract control cohort, race distribution was similar, with 0.3% American Indian or Alaska Native (277 individuals), 4.2% Asian (3809 individuals), 11.5% Black or African American (10 306 individuals), 0.8% Native Hawaiian or Other Pacific Islander (744 individuals), 55.2% White (49 598 individuals), 3.5% other race (3144 individuals), and 24.4% unknown (21 933 individuals). Ethnicity in the NAION cohort was 7.0% Hispanic or Latino (6278 individuals), 70.1% not Hispanic or Latino (62 982 individuals), and 22.9% unknown (20 551 individuals); in the control cohort, ethnicity was 6.9% Hispanic or Latino (6208 individuals), 69.3% not Hispanic or Latino (62 242 individuals), and 23.8% unknown (21 361 individuals).
A flowchart detailing the inclusion and allocation processes is shown in the Figure. Table 1 presents the baseline characteristics and underlying conditions of the NAION cohort and cataract control cohort before and after the PSM. After PSM, the SMD for all variables was less than 0.1, suggesting the achievement of balanced cohorts.
Figure. Flowchart of the Selection of Study Participants.
GCA indicates giant cell arteritis; HCO, health care organization; ICD-10, International Statistical Classification of Diseases and Related Health Problems, Tenth Revision; MS, multiple sclerosis; NAION, nonarteritic anterior ischemic optic neuropathy; and PMR, polymyalgia rheumatica.
Table 1. Baseline Characteristics of NAION Cohort and Cataract Control Cohort Before and After PSM.
| Characteristic | Before PSM | After PSM | ||||
|---|---|---|---|---|---|---|
| Participants, No. (%) | SMD | Participants, No. (%) | SMD | |||
| NAION cohort (n = 104 996) | Cataract control cohort (n = 2 001 698) | NAION cohort (n = 89 811) | Cataract control cohort (n = 89 811) | |||
| Age at index, mean (SD), y | 50.1 (24.5) | 66.5 (10.7) | 0.87a | 57.2 (18.5) | 57.0 (17.9) | 0.01 |
| Sex | ||||||
| Female | 57 209 (54.5) | 1 096 879 (54.8) | 0.01 | 49 700 (55.3) | 47 954 (55.4) | 0.04 |
| Male | 46 332 (44.1) | 817 497 (40.8) | 0.07 | 38 678 (43.1) | 40 014 (44.6) | 0.03 |
| Unknown | 1455 (1.4) | 87 322 (4.4) | 0.18a | 1433 (1.6) | 1843 (2.1) | 0.03 |
| Race | ||||||
| American Indian or Alaska Native | 324 (0.3) | 6396 (0.3) | 0.002 | 268 (0.3) | 277 (0.3) | 0.002 |
| Asian | 4434 (4.2) | 68 256 (3.4) | 0.04 | 3965 (4.4) | 3809 (4.2) | 0.01 |
| Black or African American | 11 841 (11.3) | 235 998 (11.8) | 0.02 | 10 326 (11.5) | 10 306 (11.5) | 0.001 |
| Native Hawaiian or Other Pacific Islander | 597 (0.6) | 32 779 (1.6) | 0.10a | 571 (0.6) | 744 (0.8) | 0.02 |
| White | 58 654 (55.9) | 1 118 857 (55.5) | 0.001 | 49 739 (55.4) | 49 598 (55.2) | 0.003 |
| Otherb | 3894 (3.7) | 68 368 (3.4) | 0.02 | 2937 (3.3) | 3144 (3.5) | 0.01 |
| Unknown | 25 252 (24.1) | 471 044 (23.5) | 0.01 | 22 005 (24.5) | 21 933 (24.4) | 0.002 |
| Ethnicity | ||||||
| Hispanic or Latino | 8404 (8.0) | 127 307 (6.4) | 0.06 | 6278 (7.0) | 6208 (6.9) | 0.003 |
| Not Hispanic or Latino | 74 004 (70.5) | 1 212 130 (60.6) | 0.21a | 62 982 (70.1) | 62 242 (69.3) | 0.02 |
| Unknown | 22 588 (21.5) | 646 032 (33.1) | 0.26a | 20 551 (22.9) | 21 361 (23.8) | 0.02 |
| Comorbidities | ||||||
| Diabetes | 16 797 (16.0) | 516 195 (25.7) | 0.24a | 16 745 (18.6) | 17 248 (19.2) | 0.01 |
| Dyslipidemia | 23 886 (22.7) | 693 725 (34.7) | 0.27a | 23 652 (26.3) | 23 586 (26.3) | 0.002 |
| Hypertension | 26 967 (25.7) | 801 266 (40.0) | 0.31a | 26 694 (29.7) | 27 088 (30.2) | 0.01 |
| Heart failure | 3327 (3.2) | 85 607 (4.3) | 0.06 | 3236 (3.6) | 3309 (3.7) | 0.004 |
| Atrial fibrillation and/or flutter | 3709 (3.5) | 96 300 (4.8) | 0.06 | 3695 (4.1) | 3635 (4.0) | 0.003 |
| Ischemic heart diseases | 7542 (7.2) | 210 147 (10.5) | 0.12a | 7509 (8.4) | 7437 (8.3) | 0.003 |
| Chronic kidney disease | 5139 (4.9) | 128 754 (6.4) | 0.07 | 5018 (5.6) | 5159 (5.7) | 0.01 |
| Tobacco use | 4239 (4.0) | 117 683 (5.9) | 0.09 | 4221 (4.7) | 4256 (4.7) | 0.002 |
| Obstructive sleep apnea | 5079 (4.8) | 110 824 (5.5) | 0.03 | 4660 (5.2) | 4286 (4.8) | 0.02 |
| Arteriovenous malformation of cerebral vessels | 127 (0.1) | 548 (0.03) | 0.03 | 81 (0.1) | 89 (0.1) | 0.003 |
| Other malformations of cerebral vessels | 170 (0.2) | 752 (0.04) | 0.04 | 106 (0.1) | 111 (0.1) | 0.002 |
| Nonruptured cerebral aneurysm | 561 (0.5) | 4218 (0.2) | 0.05 | 519 (0.6) | 495 (0.6) | 0.004 |
| Occlusion and stenosis of precerebral arteries | 1862 (1.8) | 31 364 (1.6) | 0.02 | 1829 (2.0) | 1561 (1.7) | 0.02 |
| Occlusion and stenosis of cerebral arteries | 158 (0.2) | 1227 (0.1) | 0.03 | 128 (0.1) | 132 (0.1) | 0.001 |
| Dural arteriovenous fistula | 139 (0.1) | 1669 (0.1) | 0.02 | 130 (0.1) | 127 (0.1) | 0.001 |
| Morbid obesity | 3133 (3.0) | 73 516 (3.7) | 0.04 | 3071 (3.4) | 2831 (3.2) | 0.02 |
| Disorders of sulfur-bearing amino acid metabolism | 94 (0.1) | 1224 (0.1) | 0.01 | 84 (0.1) | 99 (0.1) | 0.01 |
| Vitamin B12 deficiency | 379 (0.4) | 9681 (0.5) | 0.02 | 377 (0.4) | 405 (0.5) | 0.01 |
| Alcohol-related disorder | 1165 (1.1) | 31 156 (1.6) | 0.04 | 1160 (1.3) | 1175 (1.3) | 0.001 |
| Comedication | ||||||
| Antiplatelet agents | 10 860 (10.3) | 263 258 (13.2) | 0.09 | 10 721 (11.9) | 10 298 (11.5) | 0.02 |
| Anticoagulant agents | 9462 (9.0) | 188 035 (9.4) | 0.01 | 8933 (9.9) | 8357 (9.3) | 0.02 |
| Antilipemic agents | 17 230 (16.4) | 474 230 (23.7) | 0.18a | 17 167 (19.1) | 16 994 (18.9) | 0.01 |
| Oral hypoglycemic agents | 8309 (7.9) | 224 529 (11.2) | 0.11a | 8263 (9.2) | 8135 (9.1) | 0.01 |
| Insulin | 6184 (5.9) | 136 926 (6.8) | 0.04 | 6121 (6.8) | 5763 (6.4) | 0.02 |
| α-Blockers | 3469 (3.3) | 87 409 (4.4) | 0.06 | 3444 (3.8) | 3227 (3.6) | 0.01 |
| β-Blockers | 15 172 (14.5) | 346 190 (17.3) | 0.08 | 14 872 (16.6) | 15 089 (16.8) | 0.01 |
| Calcium channel blockers | 9438 (9.0) | 236 628 (11.8) | 0.09 | 9339 (10.4) | 9189 (10.2) | 0.01 |
| Diuretics | 13 839 (13.2) | 344 025 (17.2) | 0.11a | 13 244 (14.7) | 13 117 (14.6) | 0.004 |
| Angiotensin-converting enzyme inhibitors | 8825 (8.4) | 265 486 (13.3) | 0.16a | 8735 (9.7) | 9199 (10.2) | 0.02 |
| Angiotensin II inhibitors | 6449 (6.1) | 172 954 (8.6) | 0.10 | 6431 (7.2) | 6275 (7.0) | 0.01 |
Abbreviations: NAION, nonarteritic anterior ischemic optic neuropathy; PSM, propensity score matching; SMD, standardized mean difference.
Statistically significant at SMD greater than 0.1.
Includes multiracial and any other race not specified.
Main Outcomes
Table 2 shows the rate of all stroke, ischemic stroke, and hemorrhagic stroke in the NAION group compared with the cataract control group. There were 56 237 patients in the NAION cohort and 22 761 patients in the control cohort with at least 5 or 10 years of follow-up. The NAION cohort exhibited a significantly higher risk of all stroke (1 month, RR, 5.04 [95% CI, 4.41-5.78]; 3 months, RR, 3.79 [95% CI, 3.40-4.21]; 1 year, RR, 2.50 [95% CI, 2.32-2.70]; 5 years, RR, 1.54 [95% CI, 1.45-1.63]; and 10 years, RR, 1.33 [95% CI, 1.23-1.43]), ischemic stroke, and hemorrhagic stroke across all follow-up intervals, although the relative RD for hemorrhagic stroke was modest at these time points.
Table 2. Rate of All Stroke, Hemorrhagic Stroke, and Ischemic Stroke After NAION Compared With the Cataract Control Cohort in a Propensity Score–Matched Analysis.
| Follow-up interval and stroke type | RR (95% CI) | RD, % (95% CI) | Patients who experienced stroke, No. (%) | P valuea | |
|---|---|---|---|---|---|
| NAION cohort | Control cohort | ||||
| 1-mo Follow-up | |||||
| No. of patients | NA | NA | 89 811 | 89 811 | NA |
| All stroke | 5.04 (4.41-5.78) | 1.14 (1.05-1.22) | 1276 (1.42) | 253 (0.28) | <.001 |
| Hemorrhagic stroke | 7.49 (5.56-10.09) | 0.35 (0.31-0.40) | 367 (0.41) | 49 (0.06) | <.001 |
| Ischemic stroke | 4.68 (4.03-5.42) | 0.87 (0.80-0.95) | 996 (1.11) | 213 (0.24) | <.001 |
| 3-mo Follow-up | |||||
| No. of patients | NA | NA | 89 811 | 89 811 | NA |
| All stroke | 3.79 (3.40-4.21) | 1.31 (1.21-1.41) | 1598 (1.78) | 422 (0.47) | <.001 |
| Hemorrhagic stroke | 5.25 (4.18-6.58) | 0.42 (0.37-0.47) | 467 (0.52) | 89 (0.10) | <.001 |
| Ischemic stroke | 3.53 (3.14-3.98) | 0.99 (0.90-1.07) | 1237 (1.38) | 350 (0.39) | <.001 |
| 1-y Follow-up | |||||
| No. of patients | NA | NA | 89 811 | 89 811 | NA |
| All stroke | 2.50 (2.32-2.70) | 1.54 (1.42-1.67) | 2312 (2.57) | 925 (1.03) | <.001 |
| Hemorrhagic stroke | 3.20 (2.74-3.73) | 0.51 (0.45-0.58) | 668 (0.74) | 209 (0.23) | <.001 |
| Ischemic stroke | 2.35 (2.16-2.56) | 1.15 (1.04-1.26) | 1801 (2.01) | 765 (0.85) | <.001 |
| 5-y Follow-up | |||||
| No. of patients | NA | NA | 56 237 | 56 237 | NA |
| All stroke | 1.54 (1.45-1.63) | 1.74 (1.50-1.97) | 2797 (4.97) | 1821 (3.24) | <.001 |
| Hemorrhagic stroke | 1.65 (1.48-1.85) | 0.56 (0.43-0.68) | 791 (1.41) | 478 (0.85) | <.001 |
| Ischemic stroke | 1.50 (1.41-1.60) | 1.33 (1.12-1.54) | 2244 (3.99) | 1495 (2.66) | <.001 |
| 10-y Follow-up | |||||
| No. of patients | NA | NA | 22 761 | 22 761 | NA |
| All stroke | 1.33 (1.23-1.43) | 1.73 (1.29-2.17) | 1598 (7.02) | 1204 (5.29) | <.001 |
| Hemorrhagic stroke | 1.38 (1.20-1.59) | 0.54 (0.30-0.78) | 450 (1.98) | 327 (1.44) | <.001 |
| Ischemic stroke | 1.30 (1.20-1.41) | 1.33 (0.93-1.73) | 1294 (5.69) | 992 (4.36) | <.001 |
Abbreviations: NA, not applicable; NAION, nonarteritic anterior ischemic optic neuropathy; RD, risk difference; RR, relative risk.
P values were calculated for RD. All P values were statistically significant at P < .025 after the Bonferroni correction.
Risk Factor Analysis
eTable 2 in Supplement 1 details the risk factor analysis result. In summary, among all clinical factors of interest, only hypertension was consistently associated with all, hemorrhagic, and ischemic stroke within 1 and 10 years after NAION.
Sensitivity Analysis
After excluding patients with comorbidities, the NAION cohort consisted of 42 546 patients, and the cataract control cohort included 416 628 patients. A total of 29 927 patients were identified in the NAION cohort and cataract control cohort after PSM. The baseline characteristics of the refined NAION cohort and cataract control cohort before and after the PSM are shown in eTable 3 in Supplement 1. After PSM, the SMDs for all variables were less than 0.1, indicating that balanced cohorts were achieved.
Table 3 illustrates the rates of all strokes, ischemic strokes, and hemorrhagic strokes among patients without comorbidities within the NAION group compared with those in the cataract control group. There were 19 232 patients in the NAION cohort and 8326 patients in the control cohort with at least 5 or 10 years of follow-up. Generally, rates of all strokes, ischemic strokes, and hemorrhagic strokes were lower in both cohorts compared with the primary analysis. Nonetheless, consistent with the primary analysis, the risks of all strokes (1 month, RR, 7.55 [95% CI, 4.74-12.03]; 3 months, RR, 6.70 [95% CI, 4.48-10.04]; 1 year, RR, 3.96 [95% CI, 2.94-5.34]; 5 years, RR, 2.85 [95% CI, 2.18-3.72]; and 10 years, RR, 1.68 [95% CI, 1.25-2.26]), ischemic strokes, and hemorrhagic strokes following NAION were significantly higher at all the follow-up intervals. The magnitude of the RD, however, was relatively small at all these time points.
Table 3. Comparative Rates of All Stroke, Hemorrhagic Stroke, and Ischemic Stroke Among Patients Without Comorbidities Following NAION vs a Propensity Score–Matched Cataract Control Cohort.
| Follow-up interval and stroke type | RR (95% CI) | RD, % (95% CI) | Patients who experienced stroke, No. (%) | P valuea | |
|---|---|---|---|---|---|
| NAION cohort | Control cohort | ||||
| 1-mo Follow-up | |||||
| No. of patients | NA | NA | 29 927 | 29 927 | NA |
| All stroke | 7.55 (4.74-12.03) | 0.44 (0.35-0.52) | 151 (0.51) | 20 (0.07) | <.001 |
| Hemorrhagic stroke | 6.6 (3.34-12.83) | 0.19 (0.13-0.24) | 66 (0.22) | 10 (0.03) | <.001 |
| Ischemic stroke | 8.27 (4.43-15.46) | 0.27 (0.20-0.33) | 91 (0.30) | 11 (0.04) | <.001 |
| 3-mo Follow-up | |||||
| No. of patients | NA | NA | 29 927 | 29 927 | NA |
| All stroke | 6.70 (4.48-10.04) | 0.52 (0.42-0.61) | 181 (0.61) | 27 (0.09) | <.001 |
| Hemorrhagic stroke | 7.5 (3.88-14.51) | 0.22 (0.16-0.28) | 75 (0.25) | 10 (0.03) | <.001 |
| Ischemic stroke | 6.22 (3.78-10.23) | 0.31 (0.24-0.39) | 112 (0.37) | 18 (0.06) | <.001 |
| 1-y Follow-up | |||||
| No. of patients | NA | NA | 29 927 | 29 927 | NA |
| All stroke | 3.96 (2.94-5.34) | 0.54 (0.43-0.64) | 214 (0.72) | 54 (0.18) | <.001 |
| Hemorrhagic stroke | 4.53 (2.76-7.44) | 0.22 (0.16-0.29) | 86 (0.29) | 19 (0.06) | <.001 |
| Ischemic stroke | 3.72 (2.58-5.38) | 0.33 (0.24-0.41) | 134 (0.45) | 36 (0.12) | <.001 |
| 5-y Follow-up | |||||
| No. of patients | NA | NA | 19 232 | 19 232 | NA |
| All stroke | 2.85 (2.18-3.72) | 0.69 (0.52-0.86) | 205 (1.07) | 72 (0.37) | <.001 |
| Hemorrhagic stroke | 3.39 (2.13-5.40) | 0.29 (0.18-0.39) | 78 (0.41) | 23 (0.12) | <.001 |
| Ischemic stroke | 2.56 (1.86-3.52) | 0.42 (0.28-0.56) | 133 (0.69) | 52 (0.27) | <.001 |
| 10-y Follow-up | |||||
| No. of patients | NA | NA | 8326 | 8326 | NA |
| All stroke | 1.68 (1.25-2.26) | 0.56 (0.25-0.88) | 116 (1.39) | 69 (0.83) | <.001 |
| Hemorrhagic stroke | 1.94 (1.08-3.48) | 0.19 (0.03-0.36) | 33 (0.40) | 17 (0.20) | .02 |
| Ischemic stroke | 1.52 (1.09-2.12) | 0.35 (0.07-0.63) | 85 (1.02) | 56 (0.67) | .01 |
Abbreviations: NA, not applicable; NAION, nonarteritic anterior ischemic optic neuropathy; RD, risk difference; RR, relative risk.
P values were calculated for RD. All P values were statistically significant at P < .025 after the Bonferroni correction.
Discussion
In this multinational retrospective cohort study, we found a significantly elevated stroke risk among patients with NAION compared with matched controls, over both short-term and long-term periods, irrespective of comorbidities. Several risk factors are shared between NAION and stroke,1,6 prompting studies into their association, yet results remain conflicting.3,9,10,11,12,13,14 Although some studies3,9,10 have reported a significantly elevated stroke risk in patients with NAION with comorbid conditions such as diabetes and hypertension, findings regarding the entire population of patients with NAION are widely disputed. Most previous studies9,11,12,13 found no increase in stroke risk among patients with NAION, but Lee et al3 identified a significantly elevated ischemic stroke risk following NAION. Li and associates14 also found a higher ratio of ischemic stroke in patients with NAION compared with age-matched, sex-matched, and weight-matched controls. However, the controls in both studies were not matched for common comorbidities associated with stroke. Therefore, Hayreh21 argued that the increased risk was not directly caused by NAION but by the associated comorbidities. Although our study’s findings also concur with those of Lee et al3 and Li et al,14 we further consider the associations of comorbidities with stroke risk. After adjusting for comorbidities and comedications using PSM, our study still revealed a significantly elevated stroke risk following NAION. Furthermore, a sensitivity analysis of patients without comorbidities yielded a similar result. Thus, the findings of our study suggest that NAION is independently associated with increased stroke risk, regardless of the presence of comorbidities.
Hayreh21 also posited that NAION is a distinct clinical entity from cerebral ischemic stroke owing to differing underlying pathophysiology, with NAION being a hypotensive disorder and stroke a thromboembolic disorder in most cases. Consequently, he concluded that there is no direct link between NAION and stroke.21 Nonetheless, we hypothesized that strokes associated with NAION might have a different cause. Cerebrovascular diseases have 3 primary causes: large artery atherosclerosis, cardioembolism, and small vessel disease (SVD).22 Although the first 2 are the most common, SVD still contributes to 25% of ischemic strokes.23,24 Increasing evidence supports an association between cerebral SVD and NAION.13,25,26,27 In a study reviewing magnetic resonance images of 2812 patients, Kim and associates25 found a significantly higher ratio of cerebral SVD in patients with NAION than in controls after adjusting for age, sex, and comorbidities. Foster and associates13 also reported a significantly higher proportion of cerebral SVD in patients with NAION compared with controls matched for age, sex, and vascular risk factors. Therefore, these findings may indicate that NAION is associated with SVD, regardless of comorbidities. Compromised cerebral blood flow and cerebrovascular reactivity from arteriolar endothelial dysfunction are central to cerebral SVD pathophysiology.24 Given that hypoperfusion in short posterior ciliary arteries underlies NAION,1,28,29,30 and both conditions involve arterioles, a pathophysiological link is conceivable. Since cerebral SVD can cause brain damage and stroke,24 the elevated stroke risk in our study may also be attributed to cerebral SVD, beyond large artery atherosclerosis or cardioembolism. Still, further investigation is needed to clarify the connection between NAION and cerebral SVD.
The association between hemorrhagic stroke and NAION has been underexplored because of its rarity compared with ischemic stroke. Previous studies, such as those by Lee et al3 and Park et al,31 found no significant difference in hemorrhagic stroke risk between patients with NAION and controls. However, our study identified a significantly higher risk of hemorrhagic stroke in patients with NAION, regardless of comorbidities. This discrepancy may be attributed to the larger sample size and the broader racial diversity of our study population, which included patients from 17 countries, compared with the smaller, more racially homogeneous populations of earlier studies.3,31 Moreover, the significantly elevated hemorrhagic stroke risk noted in our research could also be linked to the association between cerebral SVD and NAION,13,25 considering that SVD is responsible for approximately 80% of nontraumatic intracerebral hemorrhages.32 We hypothesize that NAION can be considered a variant of SVD affecting the optic nerve, because both conditions share pathophysiological mechanisms involving compromised blood flow and vascular autoregulation at the arteriolar level.1,24,28,29,30 Consequently, the presentation of NAION may indicate that patients also exhibit some degree of SVD in their brain. This hypothesis is supported by previous studies13,25 that have demonstrated a significantly higher ratio of cerebral SVD in patients with NAION. Given that the burden of SVD is associated with an increased risk of subsequent hemorrhagic stroke,33 patients with NAION are, therefore, at an elevated risk of experiencing hemorrhagic strokes. The RD of hemorrhagic stroke between the NAION and control groups was relatively modest, likely owing to the rarity of hemorrhagic stroke compared with ischemic stroke, which accounted the majority of all strokes in our study. Still, the RD was statistically significant in both the primary and sensitivity analyses across all follow-up intervals. Therefore, our findings suggest that NAION is independently associated with increased risk of hemorrhagic stroke, regardless of comorbidities.
This study’s strengths include its large sample size, encompassing diverse data from global health care systems, making it the first, to our knowledge, multinational investigation of its kind. The unprecedented scale ensures statistically robust conclusions, with broad applicability owing to its international scope. A closely matched control population minimized the impact of comorbidities, and a sensitivity analysis of patients without comorbidities clarified NAION’s isolated impact. Finally, as far as we know, this is the only study that examines the hemorrhagic risk after NAION with a robust sample size.
Limitations
This study also has limitations. A primary concern is the potential for misclassification bias, stemming from the reliance on accurate ICD-10 diagnosis codes for identifying outcomes and conditions, including NAION. The use of ICD-10 codes alone limits our ability to assess the detailed workup and diagnostic evaluations performed. In addition, the retrospective nature of the study introduces inherent biases and limitations in data collection. The TriNetX database lacks precise information on metabolic profiles, dietary habits, physical activity levels, alcohol consumption, and the durations of comorbid conditions, all of which are factors that could potentially influence stroke development. Moreover, information on blood pressure, blood glucose levels, and body mass index was not fully available.
Conclusions
In summary, this multinational cohort study found a significantly elevated stroke rate after NAION over both short-term and long-term periods compared with matched controls, independent of comorbidities. These findings suggest that NAION may be independently associated with increased risk for stroke. Consequently, a regular stroke workup may be necessary following the onset of NAION.
eTable 1. Codes used in the study for defining conditions and drugs
eTable 2. Association between age, sex, comorbidities, and the risk of all strokes, hemorrhagic stroke, and ischemic stroke after non-arteritic anterior ischemic optic neuropathy (adjusted)
eTable 3. Baseline characteristic of NAION cohort and cataract control among patients without comorbidities before and after PSM
Data Sharing Statement
References
- 1.Hayreh SS. Ischemic optic neuropathy. Prog Retin Eye Res. 2009;28(1):34-62. doi: 10.1016/j.preteyeres.2008.11.002 [DOI] [PubMed] [Google Scholar]
- 2.Hattenhauer MG, Leavitt JA, Hodge DO, Grill R, Gray DT. Incidence of nonarteritic anterior ischemic optic neuropathy. Am J Ophthalmol. 1997;123(1):103-107. doi: 10.1016/S0002-9394(14)70999-7 [DOI] [PubMed] [Google Scholar]
- 3.Lee YC, Wang JH, Huang TL, Tsai RK. Increased risk of stroke in patients with nonarteritic anterior ischemic optic neuropathy: a nationwide retrospective cohort study. Am J Ophthalmol. 2016;170:183-189. doi: 10.1016/j.ajo.2016.08.006 [DOI] [PubMed] [Google Scholar]
- 4.Foster RC, Bhatti MT, Crum OM, Lesser ER, Hodge DO, Chen JJ. Reexamining the incidence of nonarteritic anterior ischemic optic neuropathy: a Rochester Epidemiology Project Study. J Neuroophthalmol. 2024;44(3):337-341. doi: 10.1097/WNO.0000000000002102 [DOI] [PubMed] [Google Scholar]
- 5.Miller NR, Arnold AC. Current concepts in the diagnosis, pathogenesis and management of nonarteritic anterior ischaemic optic neuropathy. Eye (Lond). 2015;29(1):65-79. doi: 10.1038/eye.2014.144 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.O’Donnell MJ, Chin SL, Rangarajan S, et al. ; INTERSTROKE investigators . Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study. Lancet. 2016;388(10046):761-775. doi: 10.1016/S0140-6736(16)30506-2 [DOI] [PubMed] [Google Scholar]
- 7.Yaghi S, Elkind MS. Lipids and cerebrovascular disease: research and practice. Stroke. 2015;46(11):3322-3328. doi: 10.1161/STROKEAHA.115.011164 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Gottesman RF, Lutsey PL, Benveniste H, et al. ; American Heart Association Stroke Council; Council on Cardiovascular and Stroke Nursing; and Council on Hypertension . Impact of sleep disorders and disturbed sleep on brain health: a scientific statement from the American Heart Association. Stroke. 2024;55(3):e61-e76. doi: 10.1161/STR.0000000000000453 [DOI] [PubMed] [Google Scholar]
- 9.Hayreh SS, Joos KM, Podhajsky PA, Long CR. Systemic diseases associated with nonarteritic anterior ischemic optic neuropathy. Am J Ophthalmol. 1994;118(6):766-780. doi: 10.1016/S0002-9394(14)72557-7 [DOI] [PubMed] [Google Scholar]
- 10.Guyer DR, Miller NR, Auer CL, Fine SL. The risk of cerebrovascular and cardiovascular disease in patients with anterior ischemic optic neuropathy. Arch Ophthalmol. 1985;103(8):1136-1142. doi: 10.1001/archopht.1985.01050080048018 [DOI] [PubMed] [Google Scholar]
- 11.Park SJ, Yang HK, Byun SJ, Park KH, Hwang JM. Risk of stroke after nonarteritic anterior ischemic optic neuropathy. Am J Ophthalmol. 2019;200:123-129. doi: 10.1016/j.ajo.2018.12.022 [DOI] [PubMed] [Google Scholar]
- 12.Hasanreisoglu M, Robenshtok E, Ezrahi D, Stiebel-Kalish H. Do patients with non-arteritic ischemic optic neuritis have increased risk for cardiovascular and cerebrovascular events? Neuroepidemiology. 2013;40(3):220-224. doi: 10.1159/000342155 [DOI] [PubMed] [Google Scholar]
- 13.Foster RC, Bhatti MT, Crum OM, et al. Stroke rate, subtype, and cardiovascular risk factors in nonarteritic anterior ischemic optic neuropathy: a population-based study. J Neuroophthalmol. 2020;40(3):328-332. doi: 10.1097/WNO.0000000000000923 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Li X, Cao X, Ma F, Jia P, Wang F, Cao X. The correlation between non-arteritic anterior ischemic optic neuropathy and cerebral infarction. Transl Neurosci. 2023;14(1):20220281. doi: 10.1515/tnsci-2022-0281 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.World Medical Association . World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191-2194. doi: 10.1001/jama.2013.281053 [DOI] [PubMed] [Google Scholar]
- 16.von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP; STROBE Initiative . The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370(9596):1453-1457. doi: 10.1016/S0140-6736(07)61602-X [DOI] [PubMed] [Google Scholar]
- 17.Yang HK, Park SJ, Byun SJ, Park KH, Kim JW, Hwang JM. Obstructive sleep apnoea and increased risk of non-arteritic anterior ischaemic optic neuropathy. Br J Ophthalmol. 2019;103(8):1123-1128. doi: 10.1136/bjophthalmol-2018-312910 [DOI] [PubMed] [Google Scholar]
- 18.Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res. 2011;46(3):399-424. doi: 10.1080/00273171.2011.568786 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Austin PC. A comparison of 12 algorithms for matching on the propensity score. Stat Med. 2014;33(6):1057-1069. doi: 10.1002/sim.6004 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Haukoos JS, Lewis RJ. The propensity score. JAMA. 2015;314(15):1637-1638. doi: 10.1001/jama.2015.13480 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Hayreh SS. Increased risk of stroke in patients with nonarteritic anterior ischemic optic neuropathy: a nationwide retrospective cohort study. Am J Ophthalmol. 2017;175:213-214. doi: 10.1016/j.ajo.2016.12.010 [DOI] [PubMed] [Google Scholar]
- 22.Chen PH, Gao S, Wang YJ, Xu AD, Li YS, Wang D. Classifying ischemic stroke, from TOAST to CISS. CNS Neurosci Ther. 2012;18(6):452-456. doi: 10.1111/j.1755-5949.2011.00292.x [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Cannistraro RJ, Badi M, Eidelman BH, Dickson DW, Middlebrooks EH, Meschia JF. CNS small vessel disease: a clinical review. Neurology. 2019;92(24):1146-1156. doi: 10.1212/WNL.0000000000007654 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Wardlaw JM, Smith C, Dichgans M. Small vessel disease: mechanisms and clinical implications. Lancet Neurol. 2019;18(7):684-696. doi: 10.1016/S1474-4422(19)30079-1 [DOI] [PubMed] [Google Scholar]
- 25.Kim MS, Jeong HY, Cho KH, et al. Nonarteritic anterior ischemic optic neuropathy is associated with cerebral small vessel disease. PLoS One. 2019;14(11):e0225322. doi: 10.1371/journal.pone.0225322 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Argyropoulou MI, Zikou AK, Tzovara I, et al. Non-arteritic anterior ischaemic optic neuropathy: evaluation of the brain and optic pathway by conventional MRI and magnetisation transfer imaging. Eur Radiol. 2007;17(7):1669-1674. doi: 10.1007/s00330-006-0506-9 [DOI] [PubMed] [Google Scholar]
- 27.Arnold AC, Hepler RS, Hamilton DR, Lufkin RB. Magnetic resonance imaging of the brain in nonarteritic ischemic optic neuropathy. J Neuroophthalmol. 1995;15(3):158-160. doi: 10.1097/00041327-199509000-00006 [DOI] [PubMed] [Google Scholar]
- 28.Arnold AC. Pathogenesis of nonarteritic anterior ischemic optic neuropathy. J Neuroophthalmol. 2003;23(2):157-163. doi: 10.1097/00041327-200306000-00012 [DOI] [PubMed] [Google Scholar]
- 29.Arnold AC, Hepler RS. Fluorescein angiography in acute nonarteritic anterior ischemic optic neuropathy. Am J Ophthalmol. 1994;117(2):222-230. doi: 10.1016/S0002-9394(14)73080-6 [DOI] [PubMed] [Google Scholar]
- 30.Kaup M, Plange N, Arend KO, Remky A. Retrobulbar haemodynamics in non-arteritic anterior ischaemic optic neuropathy. Br J Ophthalmol. 2006;90(11):1350-1353. doi: 10.1136/bjo.2006.093559 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Park SJ, Yang HK, Byun SJ, Park KH, Hwang JM. Reply. Am J Ophthalmol. 2019;203:119-120. doi: 10.1016/j.ajo.2019.02.022 [DOI] [PubMed] [Google Scholar]
- 32.Goeldlin MB, Mueller M, Siepen BM, et al. ; for Swiss Stroke Registry Investigators and SIGNAL Investigators . CADMUS: a novel MRI-based classification of spontaneous intracerebral hemorrhage associated with cerebral small vessel disease. Neurology. 2024;102(1):e207977. doi: 10.1212/WNL.0000000000207977 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Folsom AR, Yatsuya H, Mosley TH Jr, Psaty BM, Longstreth WT Jr. Risk of intraparenchymal hemorrhage with magnetic resonance imaging-defined leukoaraiosis and brain infarcts. Ann Neurol. 2012;71(4):552-559. doi: 10.1002/ana.22690 [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
eTable 1. Codes used in the study for defining conditions and drugs
eTable 2. Association between age, sex, comorbidities, and the risk of all strokes, hemorrhagic stroke, and ischemic stroke after non-arteritic anterior ischemic optic neuropathy (adjusted)
eTable 3. Baseline characteristic of NAION cohort and cataract control among patients without comorbidities before and after PSM
Data Sharing Statement